Abstract
Antithrombotic therapy (anticoagulation or antiplatelet therapy) is frequently prescribed in cancer patients for prior or new indications such as venous thromboembolism, secondary prevention of arterial thrombosis or atrial fibrillation. Therefore, it is not uncommon for thrombocytopenic cancer patients to have an indication for antithrombotic therapy. Thrombocytopenia does not reduce the risk of recurrent thrombosis. The bleeding risk with anticoagulation appears to increase when platelets are
Original language | English |
---|---|
Pages (from-to) | S68-S73 |
Number of pages | 6 |
Journal | Thrombosis Research |
Volume | 191 |
DOIs | |
Publication status | Published - Jul 2020 |
Event | 10th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) - Bergamo, Italy Duration: 17 Apr 2020 → 19 Apr 2020 |
Keywords
- Anticoagulation
- Antiplatelet therapy
- Atrial fibrillation
- Cancer
- Venous thromboembolism
- Thrombocytopenia
- ELEVATION MYOCARDIAL-INFARCTION
- ACUTE CORONARY SYNDROME
- PROPHYLACTIC PLATELET TRANSFUSIONS
- RECURRENT VENOUS THROMBOEMBOLISM
- HEMATOLOGIC MALIGNANCY PATIENTS
- STEM-CELL-TRANSPLANTATION
- MOLECULAR-WEIGHT HEPARIN
- MARROW-TRANSPLANTATION
- VENOOCCLUSIVE DISEASE
- ATRIAL-FIBRILLATION